search
Back to results

Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients

Primary Purpose

Heartburn, Gastroesophageal Reflux Disease

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Dexlansoprazole
Placebo
Sponsored by
Takeda
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heartburn focused on measuring Drug therapy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Participants identifying their main symptom as a burning feeling in the mid-epigastric area and/or chest area (that is, heartburn).
  2. Must have a history of symptomatic GERD for 6 months or longer prior to Screening with GERD symptoms that were responsive to acid-suppressive therapy.
  3. Must have episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the eDiary.

Exclusion Criteria:

  1. Has a history of cancer (except basal cell carcinoma of the skin), that has not been in remission for at least 5 years prior to Screening.
  2. Has a known history of Barrett's esophagus with dysplastic changes or any changes suspicious Barrett's seen during screening endoscopy.
  3. Participant developed acute upper gastrointestinal bleeding, gastric ulcer (a mucosal defect with white coating) or duodenal ulcer (a mucosal defect with white coating), within 30 days before the start of the Screening Visit (with the possible inclusion of those with gastric or duodenal erosion). The participant requires chronic use (greater than [>] 12 doses per month) of nonsteroidal anti-inflammatory drugs (NSAIDs) including cyclooxygenase-2 (COX-2) NSAIDs within 30 days prior to the Screening Period and throughout the study.
  4. Has comorbidities that could affect the esophagus (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal strictures); a history of radiotherapy or cryotherapy of the esophagus; and a history of corrosive or physiochemical injury (with the possible inclusion in the study of those with Schatzki's ring).
  5. Has a history of surgical procedures that may affect the esophagus (example, fundoplication and mechanical dilatation for esophageal strictures) or a history of gastric or duodenal surgery other than endoscopic removal of benign polyps.
  6. Has erosive esophagitis (EE) as shown by endoscopy, during the Screening Period.
  7. Is known to have acquired immunodeficiency syndrome (AIDS) or hepatitis, including hepatitis virus carriers: (that is, hepatitis B surface antigen HBs-antigen (HBsAg) positive or hepatitis C virus (HCV)-antibody positive).
  8. Has current or historical evidence of Zollinger-Ellison syndrome or a history of gastric acid hypersecretion.
  9. Is scheduled for surgery that requires hospitalization or requires surgical treatment during his/her participation in the study.
  10. Has donated or lost >300 milliliter (mL) blood volume, undergone plasmapheresis, or has had a transfusion of any blood product within 90 days prior to the first dose of study drug.
  11. Has a history of alcohol abuse (defined as any illicit drug use), or drug addiction in the 12 months prior to Screening.
  12. Participant with positive serology result of Helicobacter pylori (H. pylori) that needs eradication therapy during the study participation period as anticipated by the investigator.

Sites / Locations

  • Peking University First Hospital
  • Peking Union Medical College Hospital
  • Chongqing Three Gorges Central Hospital
  • Zhongshan Hospital Xiamen University
  • The People's Hospital of Guangxi Zhuang Autonomous Region
  • Affilicated Hospital of Guilin Medical University
  • Hebei General Hospital
  • Taihe Hospital
  • Central Hospital of Wuhan
  • Puai Hospital Of Wuhan City
  • The Third Hospital of Changsha
  • Zhongda Hospital Southeast
  • Affiliated Hospital of Jiangsu University
  • Wuxi people's hospital
  • The First Hospital of Jilin University
  • Shengjing Hospital of China Medical University
  • Binzhou Medical University Hospital
  • Jinan Central Hospital
  • Liaocheng Hospital
  • The Affiliated Hospital of Qingdao University
  • Renji Hospital Shanghai Jiaotong University School of Medicine
  • The First Hospital of Shanxi Medical University
  • The Second Hospital of Shanxi Medical University
  • West China Hospital,Sichuan University
  • Tianjin People's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Dexlansoprazole 30 mg

Placebo

Arm Description

Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.

Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.

Outcomes

Primary Outcome Measures

Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment
The percentage of days with neither daytime nor nighttime heartburn was equal to (=) (the days that were heartburn-free during the treatment period) / (total number of days for which either a daytime or nighttime result was marked during treatment period)*100 percent (%).

Secondary Outcome Measures

Percentage of Days Without Nighttime Heartburn During Treatment
The percentage of days without nighttime heartburn was = (the days that were heartburn-free during the treatment period) / (total number of days for which nighttime result was marked during treatment period)*100%.

Full Information

First Posted
August 17, 2016
Last Updated
July 3, 2019
Sponsor
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT02873689
Brief Title
Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients
Official Title
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
December 27, 2016 (Actual)
Primary Completion Date
March 14, 2018 (Actual)
Study Completion Date
April 19, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the efficacy and safety of dexlansoprazole compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in Chinese participants with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD).
Detailed Description
The drug being tested in this study is called dexlansoprazole. Dexlansoprazole is being tested to treat heartburn in people who have non-erosive gastroesophageal reflux disease (GERD). This study will look at heartburn relief in people who take dexlansoprazole. The study will enroll approximately 200 participants. Participants will be randomly assigned to one of the two treatment groups with 1:1 ratio -which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need): Dexlansoprazole 30 mg Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient. All participants will be asked to take one capsule at the same time each day throughout the study, and will be asked to record any time they have heartburn symptoms in a diary. This multi-center trial will be conducted in China. The overall time to participate in this study is up to 7 weeks. Participants will make 4 visits to the clinic, and will be contacted by telephone 5 to 10 days after the last dose of study drug for a follow-up assessment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heartburn, Gastroesophageal Reflux Disease
Keywords
Drug therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
217 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexlansoprazole 30 mg
Arm Type
Experimental
Arm Description
Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
Arm Title
Placebo
Arm Type
Experimental
Arm Description
Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Dexlansoprazole
Intervention Description
Dexlansoprazole delayed-release capsule
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Dexlansoprazole placebo-matching capsules
Primary Outcome Measure Information:
Title
Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment
Description
The percentage of days with neither daytime nor nighttime heartburn was equal to (=) (the days that were heartburn-free during the treatment period) / (total number of days for which either a daytime or nighttime result was marked during treatment period)*100 percent (%).
Time Frame
Up to Week 4
Secondary Outcome Measure Information:
Title
Percentage of Days Without Nighttime Heartburn During Treatment
Description
The percentage of days without nighttime heartburn was = (the days that were heartburn-free during the treatment period) / (total number of days for which nighttime result was marked during treatment period)*100%.
Time Frame
Up to Week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants identifying their main symptom as a burning feeling in the mid-epigastric area and/or chest area (that is, heartburn). Must have a history of symptomatic GERD for 6 months or longer prior to Screening with GERD symptoms that were responsive to acid-suppressive therapy. Must have episodes of heartburn for 4 or more days during the 7 days prior to Day -1 as recorded in the eDiary. Exclusion Criteria: Has a history of cancer (except basal cell carcinoma of the skin), that has not been in remission for at least 5 years prior to Screening. Has a known history of Barrett's esophagus with dysplastic changes or any changes suspicious Barrett's seen during screening endoscopy. Participant developed acute upper gastrointestinal bleeding, gastric ulcer (a mucosal defect with white coating) or duodenal ulcer (a mucosal defect with white coating), within 30 days before the start of the Screening Visit (with the possible inclusion of those with gastric or duodenal erosion). The participant requires chronic use (greater than [>] 12 doses per month) of nonsteroidal anti-inflammatory drugs (NSAIDs) including cyclooxygenase-2 (COX-2) NSAIDs within 30 days prior to the Screening Period and throughout the study. Has comorbidities that could affect the esophagus (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal strictures); a history of radiotherapy or cryotherapy of the esophagus; and a history of corrosive or physiochemical injury (with the possible inclusion in the study of those with Schatzki's ring). Has a history of surgical procedures that may affect the esophagus (example, fundoplication and mechanical dilatation for esophageal strictures) or a history of gastric or duodenal surgery other than endoscopic removal of benign polyps. Has erosive esophagitis (EE) as shown by endoscopy, during the Screening Period. Is known to have acquired immunodeficiency syndrome (AIDS) or hepatitis, including hepatitis virus carriers: (that is, hepatitis B surface antigen HBs-antigen (HBsAg) positive or hepatitis C virus (HCV)-antibody positive). Has current or historical evidence of Zollinger-Ellison syndrome or a history of gastric acid hypersecretion. Is scheduled for surgery that requires hospitalization or requires surgical treatment during his/her participation in the study. Has donated or lost >300 milliliter (mL) blood volume, undergone plasmapheresis, or has had a transfusion of any blood product within 90 days prior to the first dose of study drug. Has a history of alcohol abuse (defined as any illicit drug use), or drug addiction in the 12 months prior to Screening. Participant with positive serology result of Helicobacter pylori (H. pylori) that needs eradication therapy during the study participation period as anticipated by the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
Facility Name
Peking University First Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100032
Country
China
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Chongqing Three Gorges Central Hospital
City
Chong Qing
State/Province
Chong Qing
ZIP/Postal Code
404100
Country
China
Facility Name
Zhongshan Hospital Xiamen University
City
Xia Men
State/Province
Fu Jian
ZIP/Postal Code
361004
Country
China
Facility Name
The People's Hospital of Guangxi Zhuang Autonomous Region
City
Nan Ning
State/Province
Guang XI
ZIP/Postal Code
530022
Country
China
Facility Name
Affilicated Hospital of Guilin Medical University
City
Hai Kou
State/Province
Gui Lin
ZIP/Postal Code
570100
Country
China
Facility Name
Hebei General Hospital
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050051
Country
China
Facility Name
Taihe Hospital
City
Shi Yan
State/Province
Hu Bei
ZIP/Postal Code
442000
Country
China
Facility Name
Central Hospital of Wuhan
City
Wuhan
State/Province
Hu Bei
ZIP/Postal Code
430000
Country
China
Facility Name
Puai Hospital Of Wuhan City
City
Wuhan
State/Province
Hu Bei
ZIP/Postal Code
430000
Country
China
Facility Name
The Third Hospital of Changsha
City
Chang Sha
State/Province
Hu Nan
ZIP/Postal Code
410015
Country
China
Facility Name
Zhongda Hospital Southeast
City
Nan Jing
State/Province
Jiang Su
ZIP/Postal Code
210009
Country
China
Facility Name
Affiliated Hospital of Jiangsu University
City
Wu XI
State/Province
Jiang Su
ZIP/Postal Code
212001
Country
China
Facility Name
Wuxi people's hospital
City
Wu XI
State/Province
Jiang Su
ZIP/Postal Code
214023
Country
China
Facility Name
The First Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130000
Country
China
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110004
Country
China
Facility Name
Binzhou Medical University Hospital
City
Binzhou
State/Province
Shandong
ZIP/Postal Code
256603
Country
China
Facility Name
Jinan Central Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250013
Country
China
Facility Name
Liaocheng Hospital
City
Liaocheng
State/Province
Shandong
ZIP/Postal Code
252000
Country
China
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
ZIP/Postal Code
266003
Country
China
Facility Name
Renji Hospital Shanghai Jiaotong University School of Medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
20001
Country
China
Facility Name
The First Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030001
Country
China
Facility Name
The Second Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030001
Country
China
Facility Name
West China Hospital,Sichuan University
City
Cheng Du
State/Province
Si Chuang
ZIP/Postal Code
610041
Country
China
Facility Name
Tianjin People's Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300121
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

Learn more about this trial

Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients

We'll reach out to this number within 24 hrs